VCM
BSX icon

Vivaldi Capital Management’s Boston Scientific BSX Stock Holding History

Vivaldi Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,311
Closed -$220K – 295
2025
Q4 		$220K Sell
2,311
-121
-5% -$11.9K 0.03% 260
2025
Q3 		$237K Sell
2,432
-7
-0.3% -$725 0.03% 252
2025
Q2 		$262K Buy
2,439
+396
+19% +$40.1K 0.04% 238
2025
Q1 		$206K Buy
+2,043
New +$206K 0.03% 262

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vivaldi Capital Management's BSX Position: Q1 2026 in Review

Vivaldi Capital Management sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 2,311 shares — an estimated $220K sold.

Vivaldi Capital Management first reported a position in BSX in Q1 2025 and held it in 4 quarters. The position peaked at $262K in Q2 2025. 1,678 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Vivaldi Capital Management reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
  • Vivaldi Capital Management sold 2,311 Boston Scientific shares in Q1 2026, an estimated $220K.
  • Vivaldi Capital Management first reported a position in Boston Scientific in Q1 2025 and held it in 4 quarters.
  • Vivaldi Capital Management's Boston Scientific position peaked at $262K in Q2 2025.
  • 1,678 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Vivaldi Capital Management's 13F filing for Q1 2026, filed 14 May 2026.